Circulating TGF- β 1, glycation, and oxidation in children with diabetes mellitus type 1

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Jakuš, Vladimír ^a   Sapák, Michal ^a   Kostolanská, Jana ^b  

^a Bratislava   (Slovakia)

^b National Institute for Certified Educational Measurements   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; HEMOGLOBIN A1C; LIPID PEROXIDE; TRANSFORMING GROWTH FACTOR BETA1; FRUCTOSAMINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; METABOLIC REGULATION; OXIDATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ADOLESCENT; ADOLESCENT DEVELOPMENT; BLOOD; CHILD DEVELOPMENT; GLYCOSYLATION; HYPERGLYCEMIA; HYPOGLYCEMIA; LIPID METABOLISM; LIPID PEROXIDATION; MALE; METABOLISM; OXIDATION REDUCTION REACTION; UPREGULATION;

ADOLESCENT; ADOLESCENT DEVELOPMENT; CHILD; CHILD DEVELOPMENT; DIABETES MELLITUS, TYPE 1; FRUCTOSAMINE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; LIPID METABOLISM; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; OXIDATION-REDUCTION; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84867799874     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/510902     Document Type: Article

References (35)

1. Beisswenger P. J., Glycation and biomarkers of vascular complications of diabetes. Amino Acids 2012 42 4 1171 1183 2-s2.0-77958586155 10.1007/s00726-010-0784-z
2. Jakuš V., Rietbrock N., Advanced glycation end-products and the progress of diabetic vascular complications. Physiological Research 2004 53 2 131 142 2-s2.0-1942438654 (Pubitemid 38525116)
3. Pugliese G., Do advanced glycation end products contribute to the development of long-term diabetic complications? Nutrition, Metabolism & Cardiovascular Diseases 2008 18 7 457 460 2-s2.0-48149096878 10.1016/j.numecd.2008.06.006
4. Kashihara N., Haruna Y., Kondeti V. K., Kanwar Y. S., Oxidative stress in diabetic nephropathy. Current Medicinal Chemistry 2010 17 34 4256 4269 2-s2.0-78650657305 10.2174/092986710793348581
5. Goh S. Y., Cooper M. E., The role of advanced glycation end products in progression and complications of diabetes. The Journal of Clinical Endocrinology & Metabolism 2008 93 4 1143 1152 2-s2.0-42049118293 10.1210/jc.2007-1817 (Pubitemid 351519698)
6. Nin J. W., Jorsal A., Ferreira I., Schalkwijk C. G., Prins M. H., Parving H. H., Tarnow L., Rossing P., Stehouwer C. D., Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011 34 2 442 447 2-s2.0-79951712789 10.2337/dc10-1087
7. Mosquera J. A., Role of the receptor for advanced glycation end products (RAGE) in inflammation. Investigacion Clinica 2010 51 2 257 268 2-s2.0-78149243018
8. Son S. M., Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. Diabetes Research and Clinical Practice 2007 77 3 S65 S70 2-s2.0-34547691067 10.1016/j.diabres.2007.01.036 (Pubitemid 47212556)
9. Madonna R., De Caterina R., Cellular and molecular mechanisms of vascular injury in diabetesPart I: Pathways of vascular disease in diabetes. Vascular Pharmacology 2011 54 36 68 74 2-s2.0-79957933505 10.1016/j.vph.2011.03.005
10. Kuyvenhoven J. P., Meinders A. E., Oxidative stress and diabetes mellitus Pathogenesis of long-term complications. European Journal of Internal Medicine 1999 10 1 9 19 2-s2.0-0032926597 10.1016/S0953-6205(99)00009-6 (Pubitemid 29229660)
11. Boizel R., Bruttmann G., Benhamou P. Y., Halimi S., Stanke-Labesque F., Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes. Diabetologia 2010 53 9 2068 2070 2-s2.0-77955553599 10.1007/s00125-010-1822-9
12. Piwowar A., Advanced oxidation protein products. Part II. the significance of oxidation protein products in the pathomechanism of diabetes and its complications. Polski Merkuriusz Lekarski 2010 28 165 227 230 2-s2.0-77951181216
13. Yan S. F., Ramasamy R., Schmidt A. M., Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature Clinical Practice Endocrinology and Metabolism 2008 4 5 285 293 2-s2.0-42449109476 10.1038/ncpendmet0786 (Pubitemid 351571138)
14. Bargnoux A. S., Morena M., Badiou S., Biologie des fonctions renales et de l' insuffisance renale. Annales De Biologie Clinique 2009 67 2 153 158
15. Maeda S., Matsui T., Takeuchi M., Yoshida Y., Yamakawa R., Fukami K., Yamagishi S. I., Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacological Research 2011 63 3 241 248 2-s2.0-79751527695 10.1016/j.phrs.2010.11.008
16. Wolf G., Ziyadeh F. N., Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. NephronPhysiology 2007 106 2 p26 p31 2-s2.0-34250361947 10.1159/000101797 (Pubitemid 46920097)
17. Elmarakby A. A., Abdelsayed R., Liu J. Y., Mozaffari M. S., Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy. EPMA Journal 2010 1 1 117 129 2-s2.0-79960060540 10.1007/s13167-010-0004-7
18. Li J. H., Huang X. R., Zhu H. J., Oldfield M., Cooper M., Truong L. D., Johnson R. J., Lan H. Y., Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. The FASEB Journal 2004 18 1 176 178 2-s2.0-1342268353
19. Chung A. C. K., Zhang H., Kong Y. Z., Tan J. J., Huang X. R., Kopp J. B., Lan H. Y., Advanced glycation end-products induce tubular CTGF via TGF- β -independent Smad3 signaling. Journal of the American Society of Nephrology 2010 21 2 249 260 2-s2.0-77949395650 10.1681/ASN.2009010018
20. El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A. Y., Jurgens G., A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. Journal of Lipid Research 1989 30 4 627 630 2-s2.0-0024584235 (Pubitemid 19107750)
21. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., Nguyen-Khoa T., Nguyen A. T., Zingraff J., Jungers P., Descamps-Latscha B., Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 1996 49 5 1304 1313 2-s2.0-0029948839 (Pubitemid 26166404)
22. Kalousová M., Škrha J., Zima T., Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiological Research 2002 51 6 597 604 2-s2.0-0036972669 (Pubitemid 36168668)
23. Kostolanska J., Jakus V., Barak L., Stanikova A., Waczulikova I., Comparative study of serum/plasma glycation and lipid peroxidation of young patients with type 1 diabetes mellitus in relation to glycemic compensation and the occurrence of diabetic complications. Bratislava Medical Journal 2010 111 11 578 585 2-s2.0-78649997645
24. Kostolanská J., Jakuš V., Barák L., Staníková A., Impact of long-term glycemic control on changes of lipid profile in children and adolescents with 1 type diabetes mellitus. Vnitrni Lekarstvi 2011 57 6 533 539 2-s2.0-79960084158
25. Grainger D. J., Mosedale D. E., Metcalfe J. C., TGF- β in blood: a complex problem. Cytokine & Growth Factor Reviews 2000 11 1-2 133 145 2-s2.0-0034022167 10.1016/S1359-6101(99)00037-4 (Pubitemid 30169734)
26. Szarka A., Rigó J., Lázár L., Beko G., Molvarec A., Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunology 2010 11, article 59 1 9 2-s2.0-78649590865 10.1186/1471-2172-11-59
27. Schrijvers B. F., De Vriese A. S., Flyvbjerg A., From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrine Reviews 2004 25 6 971 1010 2-s2.0-10644259663 10.1210/er.2003-0018 (Pubitemid 39657775)
28. Hefini S., Kamel A., El-Banawy H., The role of BMP-7 and TGF-beta1 in diabetic nephropathy. Journal of Medical Research Institute 2007 28 3 235 243
29. van den Heuvel M., Batenburg W. W., Danser A. H. J., Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF- β 1 axis? Molecular and Cellular Endocrinology 2009 302 2 213 218 2-s2.0-62949147120 10.1016/j.mce.2008.09.010
30. Schaan B. D., Quadros A. S., Sarmento-Leite R., De Lucca G., Bender A., Bertoluci M., 'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease. Cardiovascular Diabetology 2007 6, article 19 1 6 2-s2.0-34548779773 10.1186/1475-2840-6-19 (Pubitemid 47430445)
31. Ibrahim S., Rashed L., Estimation of transforming growth factor-beta 1 as a marker of renal injury in type II diabetes mellitus. Saudi Medical Journal 2007 28 4 519 523 2-s2.0-34447255425 (Pubitemid 47046028)
32. Yener S., Comlekci A., Akinci B., Akan P., Demir T., Bayraktar F., Yesil S., Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones 2008 7 1 70 76 2-s2.0-42449095901
33. Huseynova G. R., Azizova G. I., Efendiyev A. M., Quantitative changes in serum IL-8, TNF- α and TGF- β 1 levels depending on compensation stage in type 2 diabetic patients. International Journal of Diabetes and Metabolism 2009 17 2 59 62 2-s2.0-74049132758
34. Azar S. T., Salti I., Zantout M. S., Major S., Alterations in plasma transforming growth factor β in normoalbuminuric type 1 and type 2 diabetic patients. The Journal of Clinical Endocrinology & Metabolism 2000 85 12 4680 4682 2-s2.0-0034485840 10.1210/jc.85.12.4680 (Pubitemid 32157651)
35. Chaturvedi N., Schalkwijk C. G., Abrahamian H., Fuller J. H., Stehouwer C. D., Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 2002 25 12 2320 2327 2-s2.0-0345249701